Technical Data
M1202-70A
Macrophage Inflammatory Protein 4, Recombinant, Human (MIP-4, CCL18)
2ug
10ug
Molecular Biology Storage: -20CShipping: RT
Recombinant Human Macrophage Inflammatory Protein-4 is a single, non-glycosylated, polypeptide chain containing 69 amino acids and having a molecular mass of 7813 Daltons.

Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be Ala-Gln-Val-Gly-Thr.

Dimers and Aggregates:
1% as determined by silver-stained SDS-PAGE gel analysis.

Biological Activity:
Murine Macrophage Inflammatory Protein-4 is fully biologically active when compared to standard. The Activity is calculated by the ability to chemoattract Human T lymphocytes at 1.0-10.0ng/ml.

Endotoxin:
0.1ng/ug (IEU/ug) of Recombinant Human MIP-4.

Protein Content:
MIP-4 protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280nm.
2. Analysis by RP-HPLC, using a calibrated solution of Recombinant Human MIP-4 as a Reference Standard.

Reconstitution:
Reconstitute the lyophilized MIP-4 in sterile 18MO-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Storage and Stability:
Lyophilized powder may be stored at 4C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.
Source: E. coli
Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.
Concentration: ~0.1mg/ml
Form: Supplied as a lyophilized powder. No additives.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis and regulation by Fc gamma receptors. Radstake TR, Van Der Voort R, De Waal Malefijt M, Figdor CG, Ann Rheum Dis 2004 Aug 26; 2. PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Struyf S, Schutyser E, Gijsbers K, Van Damme J, Am J Pathol 2003 Nov;163(5):2065-75 3. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Boot RG, Verhoek M, Hollak CE, van Meurs M, Blood 2004 Jan 1;103(1):33-9 4. Unique regulation of CCL18 production by maturing dendritic cells. Vulcano M, Struyf S, Cassatella M, Penna G, J Immunol 2003 Apr 1;170(7):3843-9 5. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. Schutyser E, Struyf S, Opdenakker G, Van de Putte I, J Biol Chem 2002 Jul 5;277(27):24584-93 6. Selective induction of CCL18/PARC by staphylococcal enterotoxins in mononuclear cells and enhanced levels in septic and rheumatoid arthritis. Schutyser E, Struyf S, Put W, Van Damme J, Eur J Immunol 2001 Dec;31(12):3755-62.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.